Seelos Therapeutics Current Ratio 2010-2022 | SEEL

Seelos Therapeutics current ratio from 2010 to 2022. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Seelos Therapeutics Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2022-03-31 $0.07B $0.01B 6.98
2021-12-31 $0.08B $0.01B 10.07
2021-09-30 $0.08B $0.01B 10.07
2021-06-30 $0.09B $0.01B 11.88
2021-03-31 $0.04B $0.01B 3.10
2020-12-31 $0.02B $0.01B 2.36
2020-09-30 $0.01B $0.00B 3.48
2020-06-30 $0.01B $0.00B 2.09
2020-03-31 $0.01B $0.01B 1.97
2019-12-31 $0.01B $0.01B 1.03
2019-09-30 $0.02B $0.01B 2.93
2019-06-30 $0.01B $0.00B 2.42
2019-03-31 $0.01B $0.01B 2.54
2018-12-31 $0.00B $0.01B 0.04
2018-09-30 $0.01B $0.00B 3.85
2018-06-30 $0.01B $0.00B 3.75
2018-03-31 $0.01B $0.00B 3.50
2017-12-31 $0.01B $0.00B 4.16
2017-09-30 $0.01B $0.00B 4.79
2017-06-30 $0.01B $0.00B 4.69
2017-03-31 $0.01B $0.00B 1.99
2016-12-31 $0.00B $0.01B 0.32
2016-09-30 $0.01B $0.01B 0.57
2016-06-30 $0.01B $0.01B 0.37
2016-03-31 $0.01B $0.01B 0.69
2015-12-31 $0.01B $0.02B 0.40
2015-09-30 $0.01B $0.01B 1.19
2015-06-30 $0.01B $0.01B 1.97
2015-03-31 $0.02B $0.01B 2.52
2014-12-31 $0.01B $0.01B 1.92
2014-09-30 $0.02B $0.01B 2.88
2014-06-30 $0.02B $0.01B 2.70
2014-03-31 $0.02B $0.02B 1.62
2013-12-31 $0.02B $0.01B 1.89
2013-09-30 $0.02B $0.01B 2.58
2013-06-30 $0.03B $0.01B 2.39
2013-03-31 $0.02B $0.01B 1.53
2012-12-31 $0.02B $0.01B 1.94
2012-09-30 $0.03B $0.02B 1.81
2012-06-30 $0.02B $0.01B 1.82
2012-03-31 $0.02B $0.01B 2.34
2011-12-31 $0.01B $0.01B 0.82
2011-09-30 $0.01B $0.00B 3.25
2011-06-30 $0.01B $0.00B 2.55
2011-03-31 $0.01B $0.00B 4.51
2010-12-31 $0.01B $0.00B 4.53
2010-09-30 $0.00B 0.00
2010-06-30 $0.01B $0.00B 2.17
2010-03-31 $0.00B $0.01B 0.27
2009-12-31 $0.00B $0.01B 0.12
2009-09-30 $0.00B $0.00B 3.67
2009-06-30 $0.00B $0.00B 2.90
2009-03-31 $0.00B $0.00B 4.22
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.067B $0.000B
Seelos Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focused on the development and advancement of novel therapeutics to address unmet medical needs for central nervous system disorders. The company's product pipeline consists of SLS-002, SLS-006, SLS-008, SLS-010 and SLS-012 which are in clinical stage. Seelos Therapeutics Inc., formerly known as Apricus Biosciences Inc., is based in New York, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.299B 9.94
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.420B 16.45
Biohaven Pharmaceutical Holding (BHVN) United States $10.085B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.716B 0.00
Emergent Biosolutions (EBS) United States $1.842B 7.89
Arcus Biosciences (RCUS) United States $1.368B 34.69
Myovant Sciences (MYOV) United Kingdom $0.984B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.517B 0.00
Gelesis Holdings (GLS) United States $0.358B 0.00
Zymeworks (ZYME) Canada $0.354B 0.00
Ambrx Biopharma (AMAM) United States $0.157B 0.00
Enzo Biochem (ENZ) United States $0.117B 24.10
SQZ Biotechnologies (SQZ) United States $0.095B 0.00